164 related articles for article (PubMed ID: 30744281)
1. [Application of restricted mean survival time in clinical follow-up study].
Yang ZJ; Lyu JJ; Hou YW; Chen Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):247-250. PubMed ID: 30744281
[TBL] [Abstract][Full Text] [Related]
2. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
4. Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.
Monnickendam G; Zhu M; McKendrick J; Su Y
Value Health; 2019 Apr; 22(4):431-438. PubMed ID: 30975394
[TBL] [Abstract][Full Text] [Related]
5. Restricted mean survival time as a summary measure of time-to-event outcome.
Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
[TBL] [Abstract][Full Text] [Related]
6. Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data.
Huang Q; Tian C
Comput Math Methods Med; 2022; 2022():7264382. PubMed ID: 36619796
[TBL] [Abstract][Full Text] [Related]
7. Dynamic RMST curves for survival analysis in clinical trials.
Liao JJZ; Liu GF; Wu WC
BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
[TBL] [Abstract][Full Text] [Related]
8. Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation.
Perego C; Sbolli M; Specchia C; Fiuzat M; McCaw ZR; Metra M; Oriecuia C; Peveri G; Wei LJ; O'Connor CM; Psotka MA
JACC Heart Fail; 2020 Dec; 8(12):973-983. PubMed ID: 33039446
[TBL] [Abstract][Full Text] [Related]
9. Omnibus test for restricted mean survival time based on influence function.
Gu J; Fan Y; Yin G
Stat Methods Med Res; 2023 Jun; 32(6):1082-1099. PubMed ID: 37015346
[TBL] [Abstract][Full Text] [Related]
10. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.
Liang F; Zhang S; Wang Q; Li W
Ann Oncol; 2018 May; 29(5):1320-1324. PubMed ID: 29788167
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.
Trinquart L; Jacot J; Conner SC; Porcher R
J Clin Oncol; 2016 May; 34(15):1813-9. PubMed ID: 26884584
[TBL] [Abstract][Full Text] [Related]
12. On the restricted mean survival time curve in survival analysis.
Zhao L; Claggett B; Tian L; Uno H; Pfeffer MA; Solomon SD; Trippa L; Wei LJ
Biometrics; 2016 Mar; 72(1):215-21. PubMed ID: 26302239
[TBL] [Abstract][Full Text] [Related]
13. Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard Ratios.
A'Hern RP
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):e75-e80. PubMed ID: 29776805
[TBL] [Abstract][Full Text] [Related]
14. The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.
Abulizi X; Ribaudo HJ; Flandre P
J Acquir Immune Defic Syndr; 2019 May; 81(1):44-51. PubMed ID: 30789450
[TBL] [Abstract][Full Text] [Related]
15. Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint.
Rulli E; Ghilotti F; Biagioli E; Porcu L; Marabese M; D'Incalci M; Bellocco R; Torri V
Br J Cancer; 2018 Dec; 119(12):1456-1463. PubMed ID: 30420618
[TBL] [Abstract][Full Text] [Related]
16. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.
Kloecker DE; Davies MJ; Khunti K; Zaccardi F
Ann Intern Med; 2020 Apr; 172(8):541-552. PubMed ID: 32203984
[TBL] [Abstract][Full Text] [Related]
17. [Interpretation and Application of Restricted Mean Survival Time].
Hasegawa T
Gan To Kagaku Ryoho; 2022 Apr; 49(4):389-396. PubMed ID: 35444119
[TBL] [Abstract][Full Text] [Related]
18. Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
Pang H; Yang G; Ho JC; Leung TH; Shi Q; Hu C; Stinchcombe TE; Wang X
Chin Clin Oncol; 2022 Feb; 11(1):7. PubMed ID: 35255696
[TBL] [Abstract][Full Text] [Related]
19. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
20. Restricted mean survival time regression model with time-dependent covariates.
Zhang C; Huang B; Wu H; Yuan H; Hou Y; Chen Z
Stat Med; 2022 Sep; 41(21):4081-4090. PubMed ID: 35746886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
